We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.75 | 0.99% | 76.55 | 55.00 | 77.24 | 76.49 | 75.43 | 76.47 | 9,026,349 | 05:00:07 |
From May 2023 to May 2024
0947 GMT - AstraZeneca is among the most mentioned companies across news items over the past six hours, according to Factiva data. The Anglo-Swedish company said the U.S. drug regulator approved its drug Lynparza as a prostate cancer treatment, and also that it has decided to discontinue the development of another drug for inflammatory bowel disease. Lynparza was approved for the treatment of metastatic castration-resistant prostate cancer after success in a phase-3 trial. The treatment will be administered in combination with abiraterone and prednisone, the company said. Separately, AstraZeneca said it has discontinued the development of monoclonal antibody brazikumab for the treatment of inflammatory bowel disease, citing the competitive landscape in drug development. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
June 01, 2023 06:02 ET (10:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
